CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-

Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.

Related Keywords

Florida , United States , Tampa , American , Roger Li , American Urological Association , Moffitt Cancer Center , Bacillus Calmette Gu , Urological Association , Annual Meetingshowed , Urothelial Cancer , Cg0070 , Pembrolizumab , Bcg Unresponsive , Core 001 , Non Muscle Invasive Bladder Cancer , Carcinoma In Situ , Cysectomy ,